[精品]顺铂联用胸腺肽和艾迪注射液治疗恶性胸腔积液的临床观察.doc

《[精品]顺铂联用胸腺肽和艾迪注射液治疗恶性胸腔积液的临床观察.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、顺钳联用胸腺肽和艾迪注射液治疗恶性胸腔积液的临床观察顺钳联用胸腺肽和艾迪注射液治疗恶性胸腔积液的临床观察【摘耍】目的：探讨顺钳联用胸腺肽和艾迪注射液在治疗恶性胸腔积液屮的疗效。方法：选择我院2003年1月〜2007年6月老年内科住院大量恶性胸腔积液患者95例，随机分成试验组和对照组，对照组45例，艾迪注注射液50ml加入0.9%生理盐水250ml中,静脉滴注，每天1次15天为1疗程，用顺钳40〜60mg,地塞米松10mg,利多卡因100mg,加入0.9%生理盐水40ml经非流管依次注入胸腔内夹管48小时，缓慢引流，每周1次用1〜4次，试验组50例在此基础上胸腔内注入胸腺肽50mg；观察症状、

2、体征、不良反应、生活质量、血常规、肝肾功、心电图等，治疗结束后6周评定疗效。结果：试验组:完全缓解15例，部分缓解28例，总有效率为86%；对照组:完全缓解9例，部分缓解16例，总有效率为55.5%,P<0.05；生活质量：试验组好转32例，占64%,对照组好转21例，占46.7%,P<0.05,具有统计学意义。两组均出现发热、恶心、呕叶•、纳差、WBC、PLT下降、肝肾功异常等不良反应，P>0.05,差异无显著性。结论:顺钳联用胸腺肽和艾迪注射液治疗恶性胸腔积液安全有效，不良反应轻微。【关键词】静脉导管；顺钳；胸腺肽；艾迪注射液；恶性胸腔积液文章编号:1009-5519(2008)01-0

3、009-02中图分类号:R73文献标识码：AClinicalobservationofcisplatincimbinedwithxiongxiantaiandaidiinjectioninmalignantpleuraleffusionWIJYing,ZHANGTing,HUANGSi—si,etal.(DepartmentofInternalMedicine,TheFirstPeople'sHospitalofNeijiang,Sichuan641000,China)[Abstract]Objective：Toinvestigatethecurativeeffectofcisplatinc

4、ombinedwithxiongxiantaiandaidiinjectioninmalignantpleuraleffusion.Methods：95patientswithmalignantpleuraleffusionselectedfromthegeriatricsdepartmentofourhospitalfromNovember2003toJune2007weredividedintoexperimentalgroupandcontrolgrouprandomly.45patientsinthecontrolgroupweretreatedwithaidiinjection50

5、mlin0.9%normalsaline250mlbyintravenousdriponceadayfor15days,cisplatin40飞0mg,dexamethoasone10mgandlidocaine100mgwereinjectedintothethoraciccavityonetofourtimes・Besidesthose,50patientsintheexperimentalgroupwereaddedwithxiongxiantai50mgbyintrathoracicinjection.Thesymptoms,physicalsigns,adversereaction

6、,qualityoflife,bloodroutineexamination,liverfunction,rendfunctionandECGwereobserved,andtheirclinicaleffectswereevaluated.Results：Intheexperimentalgroup,thecompleteremission(CR)was15cases,thepartialremission(PR)was28cases,thetotaleffectiveratewas86%；inthecontrolgroup,CRwas9cases,PR16cases,thetotalef

7、fectiveratewas55.5%,withsignificantdifferencebetweentwogroup(P<0.05).Thequalityoflifeinexperimentalgroupwasimprovedin32casesaccoutingfor64%,thequalityoflifeinthecontrolgroupwasimprovedin21caseaccoutinfor46.